(RTTNews) – The actions of Corvus Pharmaceuticals, Inc. (CRVS) rose nearly 30% on Monday morning after the drug manufacturer reported the positive effects of an initial COVID-19 study.
The CRVS is at $5. 20 lately, up $1. 13 or 27. 76% on the Nasdaq.
The clinically staged biopharmaceutical company said that new knowledge of CPI-006 Phase 1 examination, which aims to improve the immune formula by generating anti-SRAS-CoV-2 antibodies, continues to help its potential as a remedy for COVID-19. .
The effects showed higher grades of reminiscent B cells and reminiscent T cells, and no drug-related protection problems were reported in any of the 15 patients treated as of September 17.
“We continue to see consistent and promising effects with CPI-006 on patients hospitalized by COVID-19 Array. We are also exploring prospective use in combination with preventive vaccines that are being developed through third parties to prolong immunity,” said Richard Miller, President and CEO. Corvus.